Interestingly, the mobility of this abnormal antithrombin was intermediate between those of forms with 4 N-glycans and forms with 3 N-glycans, the latter being increased in PMM2-CDG patients, a rare congenital disorder of glycosylation (CDG) (Fig. 4C)4. The gene discussed is PMM2; the disease is congenital disorder of glycosylation.